Pomegranate and Hemodialysis Pilot Trial

Inflammation Clinical Trial

— POM Pilot  

Official title:

A Pilot Trial Assessing the Effect of Pomegranate Juice and Extract on Biomarkers of Oxidative Stress, Systemic Inflammation, and Monocyte Function in Hemodialysis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01562340
• Other study ID #: 41986-D
• Status: Completed
• Phase: N/A
• First received: March 21, 2012
• Last updated: May 26, 2015
• Start date: March 2012
• Est. completion date: December 2012

Study information

• Verified date: May 2015
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

In this study, the investigators will administer pomegranate juice or fruit extract as a targeted antioxidant therapy to hemodialysis patients.

The investigators will examine whether these pomegranate products will be safe and well-tolerated. The investigators will also examine whether these products may lead to improvements in blood serum biomarkers of:

• oxidative stress status

• inflammatory status

• endothelial dysfunction

Description:

There are currently more than 400,000 patients receiving chronic dialysis therapy in the United States. Cardiovascular and infectious diseases are the leading causes of death in hemodialysis patients, accounting for over 50% of all-cause mortality.

There is a complex interaction of inflammation, oxidative stress, and endothelial dysfunction in contributing to cardiovascular and infectious risk in dialysis patients. Since there is much evidence that an increase in oxidative stress contributes to risk of disease in dialysis patients, it is logical to hypothesize the antioxidant therapy may be beneficial in reducing these risks.

In addition to vitamins C and E, the most common and active antioxidant compounds that occur naturally in foods are flavonoids. Dietary flavonoids are highly bioavailable, and have been shown to confer antioxidant protection, inhibit platelet activation, exert vasorelaxant effects, and reduce inflammation in human studies. In animal model studies, dietary flavonoids have been shown to reduce the development of atherosclerosis. Polyphenols also have potent antibacterial, antifungal, and antiviral activities.

Pomegranate juice is a rich source of potent phenolic antioxidants, which have been demonstrated to have anti-atherogenic and vasorelaxant properties. Pomegranate derived polyphenols have also been demonstrated to inhibit platelet activation.

Although available data are limited, several studies suggest that dietary phenols may have beneficial effects in patients undergoing dialysis treatment. These include improvements in lipoprotein profiles, reductions in circulating inflammatory and oxidative stress biomarkers, reductions in infectious complications, and improvements in inflammatory biomarkers. These observations, though limited, suggest that polyphenol based supplementation strategies may be effective in reducing complications in those undergoing dialysis treatment.

In this study, the investigators will administer pomegranate juice and/or fruit extract as a targeted antioxidant therapy. The investigators will examine whether these pomegranate products will be safe and well-tolerated. The investigators will also examine whether these products may lead to improvements in biomarkers of oxidative stress status, inflammatory status, and endothelial dysfunction in hemodialysis patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients with end-stage renal disease receiving thrice weekly hemodialysis

• Age > 18 or < 85 years

• Life expectancy greater than one year

• Ability to understand and provide informed consent for participation in the study

Exclusion Criteria:

• History of poor adherence to hemodialysis or medical regimen

• Prisoners, patients with significant mental illness, and other vulnerable populations

• AIDS (HIV seropositivity is not an exclusion criteria)

• Active malignancy excluding basal cell carcinoma of the skin

• Gastrointestinal dysfunction requiring parenteral nutrition

• History of functional kidney transplant < 6 months prior to study entry

• Anticipated live donor kidney transplant

• Patients taking vitamin E supplements > 60 IU/day, vitamin C > 150 mg/day or other antioxidant or nutritional supplements

• Incident hemodialysis patients (defined as within 30 days of dialysis initiation)

• Patients hospitalized for more than 5 days within the past 30 days.

• Patients with a history of a major atherosclerotic event (defined as combined incidence of myocardial infarction, urgent target-vessel revascularization, coronary bypass surgery, and stroke) within three months

• Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• End Stage Renal Disease
• Inflammation
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Other:
• Pomegranate juice
Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
• Pomegranate fruit extract
Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.

Locations

Country	Name	City	State
United States	Northwest Kidney Centers	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Markers of oxidative stress	Oxidative stress: F2-isoprostanes	12 weeks	No
Primary	Markers of inflammation	Inflammation: C-reactive protein, Interleukin-6, and white blood cell count	12 weeks	No
Primary	Markers of endothelial function	Endothelial function: Monocyte functional assays (cytokines)	12 weeks	No
Secondary	Number of subjects with adverse events and type of event	Adverse reactions to pomegranate juice; Adverse reactions to pomegranate fruit extract	12 weeks	Yes

External Links

•   Kidney Research Institute at the University of Washington
•   Northwest Kidney Centers